Coverage
-
March 11, 2015
The U.S. Food and Drug Administration acted within its authority when it stripped Ranbaxy Laboratories Ltd. of tentative approvals for two generics, but the agency also made "serious errors" by granting those approvals in the first place, according to a D.C. federal court ruling unsealed Wednesday.
3 other articles on this case.
View all »